Search

Your search keyword '"Dalle, S."' showing total 1,387 results
Start Over Author "Dalle, S."
1,387 results on '"Dalle, S."'

2. Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma

Author

Blay, J.Y., Cropet, C., Mansard, S., Loriot, Y., De La Fouchardière, C., Haroche, J., Topart, D., Tougeron, D., You, B., Italiano, A., Le Brun-Ly, V., Ferrero, J.M., Penel, N., Fabbro, M., Troussard, X., Malka, D., Ray-Coquard, I., Leboulleux, S., Fléchon, A., Maubec, E., Charles, J., Dalle, S., Taieb, S., Garcia, G.C.T.E., Mandache, A.M., Colignon, N., Gavrel, M., Nowak, F., Hoog Labouret, N., Mahier Aït Oukhatar, C., and Gomez-Roca, C.

Published
2023
Full Text
View/download PDF

4. The KEYNOTE-630 Trial: A Phase 3 Study of Adjuvant Pembrolizumab in High-Risk Locally Advanced (LA) Cutaneous Squamous Cell Carcinoma (cSCC)

Author

Schenker, M., primary, Klochikhin, M., additional, Kirtbaya, D., additional, Mortier, L., additional, Gschnell, M., additional, Robert, C., additional, Meyer, N., additional, Flatz, L., additional, Dalle, S., additional, Beylot-Barry, M., additional, Eigentler, T., additional, Silverman, R. Kloss, additional, Gumuscu, B., additional, Yuan, J., additional, and Bratland, A., additional

Published
2024
Full Text
View/download PDF

5. Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data☆

Author

Di Filippo, Y., Dalle, S., Mortier, L., Dereure, O., Dalac, S., Dutriaux, C., Leccia, M.-T., Legoupil, D., Saiag, P., Brunet-Possenti, F., Arnnault, J.-P., Maubec, E., Granel-Brocard, F., De Quatrebarbes, J., Aubin, F., Lesimple, T., Beylot-Barry, M., Stoebner, P.-E., Dupuy, A., Stephan, A., Grob, J.-J., Lefevre, W., Oriano, B., Allayous, C., Lebbé, C., and Montaudié, H.

Published
2021
Full Text
View/download PDF

6. Predictors of responses to immune checkpoint blockade in advanced melanoma.

Author

Jacquelot, N, Roberti, MP, Enot, DP, Rusakiewicz, S, Ternès, N, Jegou, S, Woods, DM, Sodré, AL, Hansen, M, Meirow, Y, Sade-Feldman, M, Burra, A, Kwek, SS, Flament, C, Messaoudene, M, Duong, CPM, Chen, L, Kwon, BS, Anderson, AC, Kuchroo, VK, Weide, B, Aubin, F, Borg, C, Dalle, S, Beatrix, O, Ayyoub, M, Balme, B, Tomasic, G, Di Giacomo, AM, Maio, M, Schadendorf, D, Melero, I, Dréno, B, Khammari, A, Dummer, R, Levesque, M, Koguchi, Y, Fong, L, Lotem, M, Baniyash, M, Schmidt, H, Svane, IM, Kroemer, G, Marabelle, A, Michiels, S, Cavalcanti, A, Smyth, MJ, Weber, JS, Eggermont, AM, and Zitvogel, L

Abstract

Immune checkpoint blockers (ICB) have become pivotal therapies in the clinical armamentarium against metastatic melanoma (MMel). Given the frequency of immune related adverse events and increasing use of ICB, predictors of response to CTLA-4 and/or PD-1 blockade represent unmet clinical needs. Using a systems biology-based approach to an assessment of 779 paired blood and tumor markers in 37 stage III MMel patients, we analyzed association between blood immune parameters and the functional immune reactivity of tumor-infiltrating cells after ex vivo exposure to ICB. Based on this assay, we retrospectively observed, in eight cohorts enrolling 190 MMel patients treated with ipilimumab, that PD-L1 expression on peripheral T cells was prognostic on overall and progression-free survival. Moreover, detectable CD137 on circulating CD8+ T cells was associated with the disease-free status of resected stage III MMel patients after adjuvant ipilimumab + nivolumab (but not nivolumab alone). These biomarkers should be validated in prospective trials in MMel.The clinical management of metastatic melanoma requires predictors of the response to checkpoint blockade. Here, the authors use immunological assays to identify potential prognostic/predictive biomarkers in circulating blood cells and in tumor-infiltrating lymphocytes from patients with resected stage III melanoma.

Published
2017

7. Updated outcomes of AdjuMel study: real-world data in patients with resected stage III-IV melanoma treated with adjuvant nivolumab in France

Author

Dalle, S., primary, Saiag, P., additional, Lebbé, C., additional, Grob, J.-J., additional, Dréno, B., additional, Dalac, S., additional, Asselain, B., additional, Skowron, F., additional, Darras, S., additional, Jovenin, N., additional, Quereux, G., additional, Khammari, A., additional, Rieuf, C., additional, Brellier, F., additional, Houssou, S., additional, and Mortier, L., additional

Published
2024
Full Text
View/download PDF

8. Early recurrence in a pooled international cohort of melanoma patients treated with adjuvant nivolumab in a real-world setting

Author

Mortier, L., primary, Gutzmer, R., additional, Atkinson, V., additional, Dalle, S., additional, Saiag, P., additional, Neyns, B., additional, Rorive, A., additional, Parente, P., additional, Weichenthal, M., additional, Grob, J.-J., additional, Lebbé, C., additional, Mohr, P., additional, Eigentler, T., additional, McDonald, L., additional, Willemot, L., additional, Brellier, F., additional, Bakharevski, O., additional, Houssou, S., additional, Jadhao, M., additional, and Schadendorf, D., additional

Published
2024
Full Text
View/download PDF

12. Étude d’efficacité et de tolérance en vie réelle des patients atteints de mélanome métastatique traités en première ligne par ipilimumab + nivolumab versus nivolumab

Author

Billard, K., primary, Mortier, L., additional, Dereure, O., additional, Dalac, S., additional, Montaudié, H., additional, Legoupil, D., additional, Dutriaux, C., additional, De Quatrebarbes, J., additional, Maubec, E., additional, Leccia, M.T., additional, Granel-Brocard, F., additional, Brunet-Possenti, F., additional, Arnault, J.P., additional, Gaudy-Marqueste, C., additional, Cécile, P., additional, Saiag, P., additional, L’orphelin, J.M., additional, Zehou, O., additional, Lesimple, T., additional, Allayous, C., additional, Oriano, B., additional, Dalle, S., additional, and Lebbé, C., additional

Published
2023
Full Text
View/download PDF

13. Bilan à 10 ans de la plus grande cohorte française de patients atteints d’un mélanome

Author

Cassecuel, J., primary, Dalle, S., additional, Montaudié, H., additional, Dupuy, A., additional, Dereure, O., additional, Mortier, L., additional, Amini-Adle, M., additional, Leccia, M.T., additional, Grange, F., additional, Célérier, P., additional, Maubec, E., additional, Dalac-Rat, S., additional, Khammari, A., additional, Lebbé, C., additional, and Quéreux, G., additional

Published
2023
Full Text
View/download PDF

19. Nevos

Author

Perier-Muzet, M., primary and Dalle, S., additional

Published
2023
Full Text
View/download PDF

20. Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

Author

Kennedy, O.J., Kicinski, M., Valpione, S., Gandini, S., Suciu, S., Blank, C.U., Long, G.V., Atkinson, V.G., Dalle, S., Haydon, A.M., Meshcheryakov, A., Khattak, A., Carlino, M.S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P.A., Rutkowski, P., Schadendorf, D., Boers-Sonderen, M.J., Giacomo, A.M. Di, Eertwegh, A.J.M. van den, Grob, J.J., Gutzmer, R., Jamal, R., Akkooi, A.C.J. van, Robert, C., Eggermont, A.M.M., Lorigan, P., Mandala, M., Kennedy, O.J., Kicinski, M., Valpione, S., Gandini, S., Suciu, S., Blank, C.U., Long, G.V., Atkinson, V.G., Dalle, S., Haydon, A.M., Meshcheryakov, A., Khattak, A., Carlino, M.S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P.A., Rutkowski, P., Schadendorf, D., Boers-Sonderen, M.J., Giacomo, A.M. Di, Eertwegh, A.J.M. van den, Grob, J.J., Gutzmer, R., Jamal, R., Akkooi, A.C.J. van, Robert, C., Eggermont, A.M.M., Lorigan, P., and Mandala, M.

Abstract

01 augustus 2023, Item does not contain fulltext, BACKGROUND: Metformin is a commonly prescribed and well-tolerated medication. In laboratory studies, metformin suppresses BRAF wild-type melanoma cells but accelerates the growth of BRAF-mutated cells. This study investigated the prognostic and predictive value of metformin, including with respect to BRAF mutation status, in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 randomised controlled trial. METHODS: Patients with resected high-risk stage IIIA, IIIB, or IIIC melanoma received 200 mg of pembrolizumab (n = 514) or placebo (n = 505) every 3 weeks for twelve months. Pembrolizumab prolonged recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) at approximately 42 months median follow-up (Eggermont et al., TLO, 2021). Multivariable Cox regression was used to estimate associations of metformin with RFS and DMFS. Interaction terms were used to model effect modification by treatment and BRAF mutation. RESULTS: Fifty-four patients (0.5%) used metformin at baseline. Metformin was not significantly associated with RFS (hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.52-1.45) and DMFS (HR 0.82, 95% CI 0.47-1.44). The interaction between metformin and the treatment arm was not significant for either RFS (p = 0.92) or DMFS (p = 0.93). Among patients with mutated BRAF, the association of metformin with RFS (HR 0.70, 95% CI 0.37-1.33) was greater in magnitude though not significantly different to those without mutated BRAF (HR 0.98, 95% CI 0.56-1.69). CONCLUSIONS: There was no significant impact of metformin use on pembrolizumab efficacy in resected high-risk stage III melanoma. However, larger studies or pooled analyses are needed, particularly to explore a possible effect of metformin in BRAF-mutated melanoma.

Published
2023

22. Inflammation oculaire induite par les inhibiteurs du checkpoint immunitaire

Author

Chaudot, F., primary, Sève, P., additional, Rousseau, A., additional, Alexandre, M., additional, Fournie, P., additional, Lozac’h, P., additional, Keraen, J., additional, Servant, M., additional, Muller, R., additional, Gramont, B., additional, Touhami, S., additional, Mahmoud, H., additional, Quintart, P.A., additional, Dalle, S., additional, Lambotte, O., additional, Kodjikian, L., additional, and Jamilloux, Y., additional

Published
2022
Full Text
View/download PDF

23. Mutations BRAF non-V600E/K dans le mélanome métastatique : description moléculaire, fréquence, et efficacité de la thérapie ciblée dans une cohorte nationale prospective

Author

Girod, M., primary, Dalle, S., additional, Mortier, L., additional, Dalac, S., additional, Leccia, M.T., additional, Dutriaux, C., additional, Montaudié, H., additional, De Quatrebarbes, J., additional, Lesimple, T., additional, Brunet Possenti, F., additional, Saiag, P., additional, Maubec, E., additional, Legoupil, D., additional, Stoebner, P.E., additional, Arnault, J.P., additional, Lefebvre, W., additional, Lebbé, C., additional, and Dereure, O., additional

Published
2022
Full Text
View/download PDF

26. Comparaison de l’efficacité et de la tolérance des traitements systémiques dans le mélanome avancé de primitif inconnu vs de primitif cutané: étude multicentrique rétrospective de la cohorte nationale MELBASE

Author

Rousset, P., primary, Dalle, S., additional, Mortier, L., additional, Dereure, O., additional, Dalac, S., additional, Dutriaux, C., additional, Leccia, M.T., additional, Legoupil, D., additional, Brunet Possenti, F., additional, De Quatrebarbes, J., additional, Grob, J.J., additional, Saiag, P., additional, Maubec, E., additional, Stoebner, P.E., additional, Granel-Brocard, F., additional, Arnault, J.P., additional, Allayous, C., additional, Oriano, B., additional, Lebbé, C., additional, and Montaudié, H., additional

Published
2022
Full Text
View/download PDF

27. Efficacité sur la survie globale de la poursuite de l’immunothérapie à la progression dans le mélanome avancé : estimation à partir de la cohorte MELBASE

Author

Macaire, C., primary, Lefevre, W., additional, Dalac, S., additional, Montaudié, H., additional, Legoupil, D., additional, Dereure, O., additional, Dutriaux, C., additional, Leccia, M.T., additional, Aubin, F., additional, Grob, J.J., additional, Saiag, P., additional, De Quatrebarbes, J., additional, Maubec, E., additional, Lesimple, T., additional, Granel-Brocard, F., additional, Mortier, L., additional, Dalle, S., additional, Lebbé, C., additional, and Prod’homme, C., additional

Published
2022
Full Text
View/download PDF

31. Prise en charge en vie réelle des patients atteints de mélanome de stade III ou IV réséqué par immunothérapie et thérapie ciblée en situation adjuvante

Author

Denyset, M., primary, Dalle, S., additional, Leccia, M.T., additional, Bernard, P., additional, Grange, F., additional, Dalac, S., additional, Célérier, P., additional, Adle, A., additional, Maubec, E., additional, Zehou, O., additional, Lesage, C., additional, Bens, G., additional, Possenti, F. Brunet, additional, Skowron, F., additional, Muller, P., additional, Geoffroy, L., additional, Misery, L., additional, Jouary, T., additional, Mortier, L., additional, Litrowski, N., additional, De Quatrebarbes, J., additional, Safia, A., additional, Montaudié, H., additional, Leduc, N., additional, Le Corre, Y., additional, Khammari, A., additional, and Quéreux, G., additional

Published
2022
Full Text
View/download PDF

32. NIVO + RELA vs NIVO dans le mélanome métastatique ou non résécable précédemment non traité : survie globale et taux de réponse objective par sous-groupes clés de l’étude RELATIVITY-047

Author

Grob, J.J., primary, Tawbi, H.A., additional, Hodi, S., additional, Lipson, E.J., additional, Schadendorf, D., additional, Ascierto, P.A., additional, Matamala, L., additional, Salman, P., additional, Castillo Gutiérrez, E., additional, Rutkowski, P., additional, Gogas, H.J., additional, Lao, C.D., additional, De Menezes, J.J., additional, Dalle, S., additional, Arance, A., additional, Keidel, S., additional, Jonczak, K., additional, Sobiesk, A.M., additional, Dolfi, S., additional, and Long, G., additional

Published
2022
Full Text
View/download PDF

34. 844P Efficacy and safety of lifileucel, an investigational autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma previously treated with anti-LAG3 antibody

Author

Larkin, J., primary, Dalle, S., additional, Sanmamed, M.F., additional, Wilson, M., additional, Hassel, J.C., additional, Kluger, H., additional, Orloff, M., additional, Weber, J.S., additional, Graf Finckenstein, F., additional, Hari, P., additional, Jagasia, M., additional, Yin, H., additional, Shi, W., additional, Sulur, G., additional, Wu, X., additional, Gontcharova, V., additional, and Lewis, K., additional

Published
2022
Full Text
View/download PDF

35. 817P Nivolumab (NIVO) + relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: Additional response outcomes from RELATIVITY-047

Author

Hodi, F.S., primary, Tawbi, H.A., additional, Lipson, E.J., additional, Schadendorf, D., additional, Ascierto, P.A., additional, Matamala, L.A., additional, Salman, P., additional, Gutierrez, E.C., additional, Rutkowski, P., additional, Gogas, H.J., additional, Lao, C.D., additional, Menezes, J., additional, Dalle, S., additional, Arance Fernandez, A.M., additional, Grob, J.J., additional, Keidel, S., additional, Rodriguez, S., additional, Wang, P., additional, Dolfi, S., additional, and Long, G.V., additional

Published
2022
Full Text
View/download PDF

36. Lacutamab in patients with advanced mycosis fungoides according to KIR3DL2 expression: stage 1 results from the TELLOMAK phase 2 trial

Author

Bagot, M, primary, Muller, M, additional, Kim, YH, additional, Ortiz-Romero, PL, additional, Zinzani, PL, additional, Beylot-Barry, M, additional, Dalle, S, additional, Jacobsen, E, additional, Combalia, A, additional, Huen, A, additional, Mehta-Shah, N, additional, Khodadoust, MS, additional, Viotti, J, additional, Paiva, C, additional, and Porcu, P, additional

Published
2022
Full Text
View/download PDF

37. 804P Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial

Author

Eggermont, A.M.M., primary, Kicinski, M., additional, Blank, C.U., additional, Mandala, M., additional, Long, G.V., additional, Atkinson, V.G., additional, Dalle, S., additional, Haydon, A.M., additional, Meshcheryakov, A., additional, Khattak, A., additional, Carlino, M.S., additional, Sandhu, S.K., additional, Puig Sarda, S.S., additional, Ascierto, P.A., additional, Lorigan, P., additional, Grebennik, D., additional, Ibrahim, N., additional, Marreaud, S.I., additional, Suciu, S., additional, and Robert, C., additional

Published
2022
Full Text
View/download PDF

38. LBA44 Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Long-term quality of life analysis results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial

Author

Bottomley, A., primary, Kicinski, M., additional, Long, G.V., additional, Mandala, M., additional, Atkinson, V.G., additional, Blank, C.U., additional, Haydon, A.M., additional, Dalle, S., additional, Khattak, A., additional, Carlino, M.S., additional, Meshcheryakov, A., additional, Sandhu, S.K., additional, Sarda, S.S. Puig, additional, Coens, C., additional, Suciu, S., additional, Grebennik, D., additional, Krepler, C., additional, Lorigan, P., additional, Robert, C., additional, and Eggermont, A.M.M., additional

Published
2022
Full Text
View/download PDF

41. 1095P Pembrolizumab versus placebo after a complete resection of high-risk stage III melanoma: 7-year results of the EORTC 1325-MG/Keynote-054 double-blind phase III trial

Author

Eggermont, A.M.M., Kicinski, M., Blank, C.U., Mandalà, M., Long, G.V., Atkinson, V.G., Dalle, S., Haydon, A.M., Meshcheryakov, A., Khattak, M.A., Carlino, M.S., Sandhu, S.K., Puig Sarda, S., Ascierto, P.A., Lorigan, P., Grebennik, D., Krepler, C., Marreaud, S.I., Suciu, S., and Robert, C.

Published
2024
Full Text
View/download PDF

50. Clinical, histopathological and prognostic features of primary cutaneous acral CD8+ T-cell lymphoma and other dermal CD8+ cutaneous lymphoproliferations: results of an EORTC Cutaneous Lymphoma Group workshop*

Author

Kempf, W., Petrella, T., Willemze, R., Jansen, P., Berti, E., Santucci, M., Geissinger, E., Cerroni, L., Maubec, E., Battistella, M., Goodlad, J., Guenova, E., Lappalainen, K., Ranki, A., Craig, P., Calonje, E., Martin, B., Whittaker, S., Oschlies, I., Wehkamp, U., Nicolay, J. P., Wobser, M., Scarisbruck, J., Pimpinelli, N., Stadler, R., Kerl French, K., Quaglino, P., Lin, J., Chen, L., Beer, M., Emanuel, P., Dalle, S., and Robson, A.

Subjects
Cutaneous, Skin Neoplasms, Lymphoma, CD8-Positive T-Lymphocytes, Humans, Prognosis, Retrospective Studies, Lymphoma, T-Cell, Cutaneous, T-Cell
Published
2022

Catalog

Books, media, physical & digital resources
See catalog results